Karyopharm Therapeutics Inc.
KPTI
$4.59
-$0.05-1.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 57.27% | 46.60% | 37.41% | 36.50% | 7.39% |
| Total Depreciation and Amortization | 2.46% | -35.85% | -40.64% | -50.15% | -55.72% |
| Total Amortization of Deferred Charges | 963.82% | 682.43% | 424.04% | 152.11% | 0.74% |
| Total Other Non-Cash Items | -549.22% | -426.34% | -345.93% | -297.40% | -44.19% |
| Change in Net Operating Assets | -13.27% | -100.96% | -50.97% | -104.43% | -36.03% |
| Cash from Operations | -4.43% | -37.49% | -19.09% | -30.57% | -7.57% |
| Capital Expenditure | 127.18% | -- | -- | -400.00% | -400.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.11% | 1,104.22% | 227.92% | 242.82% | 150.96% |
| Cash from Investing | 42.64% | 1,102.43% | 227.69% | 242.44% | 150.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 29.18% | 29.18% | -99.34% | -99.36% | -99.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,605.16% | 3,605.16% | -73.69% | -74.63% | -99.31% |
| Foreign Exchange rate Adjustments | 300.00% | 67.65% | 3,166.67% | 166.67% | 98.87% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.28% | 111.50% | 200.39% | 249.84% | 21.93% |